About urogen pharma ltd - URGN
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
URGN At a Glance
UroGen Pharma Ltd.
400 Alexander Park Drive
Princeton, New Jersey 08540
| Phone | 1-646-768-9780 | Revenue | 90.40M | |
| Industry | Biotechnology | Net Income | -126,874,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 9.291% | |
| Fiscal Year-end | 12 / 2025 | Employees | 235 | |
| View SEC Filings |
URGN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.051 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.596 |
| Enterprise Value to Sales | 3.803 |
| Total Debt to Enterprise Value | 0.363 |
URGN Efficiency
| Revenue/Employee | 384,672.34 |
| Income Per Employee | -539,889.362 |
| Receivables Turnover | 4.453 |
| Total Asset Turnover | 0.39 |
URGN Liquidity
| Current Ratio | 6.01 |
| Quick Ratio | 5.809 |
| Cash Ratio | 5.174 |
URGN Profitability
| Gross Margin | 90.176 |
| Operating Margin | -107.062 |
| Pretax Margin | -137.218 |
| Net Margin | -140.35 |
| Return on Assets | -54.684 |
| Return on Equity | N/A |
| Return on Total Capital | -109.267 |
| Return on Invested Capital | -170.567 |
URGN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 107.581 |
| Total Debt to Total Assets | 43.721 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 106.264 |